(Q44769237)

English

Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy

scientific article published in December 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 December 2017

Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy (English)

1 reference

Europe PubMed Central

6 December 2017

1 reference

based on heuristic

inferred from title

Kazuaki Chayama

17

object named as

Kazuaki Chayama

1 reference

Europe PubMed Central

6 December 2017

2

object named as

Hiroshi Aikata

1 reference

Europe PubMed Central

6 December 2017

Tomokazu Kawaoka

11

object named as

Tomokazu Kawaoka

1 reference

Europe PubMed Central

6 December 2017

Shoichi Takahashi

13

object named as

Shoichi Takahashi

1 reference

Europe PubMed Central

6 December 2017

Akira Hiramatsu

12

object named as

Akira Hiramatsu

1 reference

Europe PubMed Central

6 December 2017

Takashi Nakahara

10

object named as

Takashi Nakahara

1 reference

Europe PubMed Central

6 December 2017

16

object named as

Kazuo Awai

1 reference

Europe PubMed Central

6 December 2017

4

object named as

Hatsue Fujino

1 reference

Europe PubMed Central

6 December 2017

3

object named as

Hiromi Kan

1 reference

Europe PubMed Central

6 December 2017

Tomoki Kobayashi

8

object named as

Tomoki Kobayashi

1 reference

Europe PubMed Central

6 December 2017

Takayuki Fukuhara

7

object named as

Takayuki Fukuhara

1 reference

Europe PubMed Central

6 December 2017

author name string

Daisuke Miyaki

1

1 reference

Europe PubMed Central

6 December 2017

Ayako Urabe

5

1 reference

Europe PubMed Central

6 December 2017

Keiichi Masaki

6

1 reference

Europe PubMed Central

6 December 2017

Noriaki Naeshiro

9

1 reference

Europe PubMed Central

6 December 2017

Masaki Ishikawa

14

1 reference

Europe PubMed Central

6 December 2017

Hideaki Kakizawa

15

1 reference

Europe PubMed Central

6 December 2017

publication date

1 December 2013

1 reference

Europe PubMed Central

6 December 2017

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

6 December 2017

28

1 reference

Europe PubMed Central

6 December 2017

12

1 reference

Europe PubMed Central

6 December 2017

1834-1841

1 reference

Europe PubMed Central

6 December 2017

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009).

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12311

21 January 2018

Identifiers

10.1111/JGH.12311

1 reference

Europe PubMed Central

6 December 2017

1 reference

Europe PubMed Central

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44769237&oldid=2040231086"